Cell Death Differ+Cardiovasc Res:发现血小板寿命与功能调控新机制

2019-02-13 MedSci 北京大学

近日,北京大学分子医学研究所马淇博士与合作者分别在Cell Death and Differentation(CDD)和Cardiovascular Research(CVR)上发表最新研究成果,鉴定了一个调控血小板寿命和功能的新分子,并研究了其调控机制。

近日,北京大学分子医学研究所马淇博士与合作者分别在Cell Death and Differentation(CDD)和Cardiovascular Research(CVR)上发表最新研究成果,鉴定了一个调控血小板寿命和功能的新分子,并研究了其调控机制。

血小板对机体的止血功能和血栓形成至关重要,主要由骨髓中巨核细胞脱落的胞浆碎片组成。线粒体作为细胞中能量供应的细胞器,兼具信号转导中心的双重功能,因此,线粒体对于血小板这类没有细胞核的细胞尤为重要。

作者首先鉴定了一个全新的线粒体蛋白FUNDC2。实验证实FUNDC2定位在线粒体外膜,其N端的功能域可以特异性的结合磷脂酰肌醇三磷酸(PIP3)。FUNDC2招募PIP3在线粒体上富集,并激活线粒体上的AKT信号通路。进一步的研究发现FUNDC2通过AKT调控血小板的凋亡和寿命,兼具调控血小板聚集的功能。FUNDC2敲除的小鼠表现出血小板数量减少和血小板功能缺陷,在凝血和血栓形成中均有障碍。

此项研究拓展了血小板功能调控领域的研究方向,并为针对血小板的药物开发和治疗提供了新的视野。


线粒体蛋白FUNDC2调控血小板寿命与功能的分子机制:(1)FUNDC2调控血小板生存的信号通路;(2)FUNDC2激活血小板的信号通路。

原始出处:


2.Ma Q,et al.FUNDC2 regulates platelet activation through AKT/GSK-3β/cGMP axis.Cardiovasc Res. 2018 Dec 21.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1871149, encodeId=650a18e1149a7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Aug 01 07:41:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961426, encodeId=d85f196142684, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Apr 15 13:41:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938916, encodeId=dc7619389166c, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Dec 11 12:41:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784215, encodeId=da4b1e8421554, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed Jun 26 11:41:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531463, encodeId=61b41531463f9, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri Feb 15 10:41:00 CST 2019, time=2019-02-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1871149, encodeId=650a18e1149a7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Aug 01 07:41:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961426, encodeId=d85f196142684, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Apr 15 13:41:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938916, encodeId=dc7619389166c, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Dec 11 12:41:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784215, encodeId=da4b1e8421554, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed Jun 26 11:41:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531463, encodeId=61b41531463f9, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri Feb 15 10:41:00 CST 2019, time=2019-02-15, status=1, ipAttribution=)]
    2019-04-15 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1871149, encodeId=650a18e1149a7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Aug 01 07:41:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961426, encodeId=d85f196142684, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Apr 15 13:41:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938916, encodeId=dc7619389166c, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Dec 11 12:41:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784215, encodeId=da4b1e8421554, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed Jun 26 11:41:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531463, encodeId=61b41531463f9, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri Feb 15 10:41:00 CST 2019, time=2019-02-15, status=1, ipAttribution=)]
    2019-12-11 quxin068
  4. [GetPortalCommentsPageByObjectIdResponse(id=1871149, encodeId=650a18e1149a7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Aug 01 07:41:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961426, encodeId=d85f196142684, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Apr 15 13:41:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938916, encodeId=dc7619389166c, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Dec 11 12:41:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784215, encodeId=da4b1e8421554, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed Jun 26 11:41:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531463, encodeId=61b41531463f9, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri Feb 15 10:41:00 CST 2019, time=2019-02-15, status=1, ipAttribution=)]
    2019-06-26 isabellayj
  5. [GetPortalCommentsPageByObjectIdResponse(id=1871149, encodeId=650a18e1149a7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Aug 01 07:41:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961426, encodeId=d85f196142684, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Apr 15 13:41:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938916, encodeId=dc7619389166c, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Dec 11 12:41:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784215, encodeId=da4b1e8421554, content=<a href='/topic/show?id=f01159527d' target=_blank style='color:#2F92EE;'>#Differ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5952, encryptionId=f01159527d, topicName=Differ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Wed Jun 26 11:41:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531463, encodeId=61b41531463f9, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri Feb 15 10:41:00 CST 2019, time=2019-02-15, status=1, ipAttribution=)]
    2019-02-15 cy0328

相关资讯

Blood:诱导脂肪间充质干细胞分化成血小板有望缓解临床血小板输注需求压力

临床对输血小板的需求正在增加。但是,供体依赖性的血小板输注存在很多实际问题,如供应有限和感染风险。Keiichi Tozawa等人尝试开发不依赖于供细胞来源的血小板的制造系统,即人类脂肪间充质基质/干细胞系(ASCL)。采用倒置培养瓶法可获得ASCL。ASCL满足国际细胞治疗学会所定义的间充质干细胞(MSC)的最低标准。ASCL的增殖能力至少可维持2个月,且无任何异常核型。可采用巨核细胞诱导型培养

Lancet N:PFO 应该抗凝还是抗血小板?

卵圆孔未闭(PFO)是隐源性卒中的潜在病因。六项试验验乞过设备封堵 PFO对缺血性卒中的作用,三项显示能够显著降低卒中复发(ITT 分析),两项 meta 分析支持封堵术优于内科治疗。在这些临床试验中仅有一项试验允许抗凝治疗作为内科治疗的选项,封堵术的获益主要存在于与抗血小板治疗的比较中,而不是抗凝治疗。与 PFO 相关的卒中大部分被认为是矛盾性栓塞,栓子起源于静脉血栓,并且大量数据显示对于预防和

JACC:氯吡格雷血小板反应性对TAVR后低密度小叶增厚发病率的影响

氯吡格雷ADP诱导的PR与HALT的发生无显著相关性。相反,口服抗凝药物与HALT的发病率降低有关。

CATHETER CARDIO INTE:阜外医院窦克非等研究称,介入患者血小板减少不增加出血风险

阜外医院窦克非等研究提示,接受PCI的患者中,基线血小板减少症很常见,但它不会影响预后,尤其是不会增加出血风险。

Blood:巨核细胞可通过诱导IFITM3表达预防病毒感染

中心点:病毒感染可上调人血小板和巨核细胞的IFITM3,触发快速的抗病毒免疫反应。MKs是一种有效的免疫细胞,可预防病毒感染,也可预防临近造血干细胞感染。摘要:越来越多的证据表明血小板和巨核细胞(MKs)在炎症和感染中发挥意想不到的活性;但目前尚不明确病毒感染是否可上调血小板和MKs的具有生物活性的抗病毒免疫基因。Robert A. Campbell等人检测了登革热和流感病毒感染时的这类细胞的抗病

血小板仅仅为“6”,究竟发生了什么?

018年11月15日,一张心内科住院患者的血常规报告单引起了审发报告员的高度注意,患者的血小板为6×109/L,这么低?首先考虑是否有凝块,检查标本未见凝块。再看报告单,白细胞和红细胞不算低啊,查询最近的历史结果三系大致正常:血红蛋白浓度132g/L,PLT为191×109/L,咋回事?血常规报告单如下: